Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Perclose

This article was originally published in The Gray Sheet

Executive Summary

Perclose: Completes human testing of its two-suture Prostar Plus 8F percutaneous vascular surgical system, a second-generation device for vascular closure of the arterial access sites created by catheterization procedures. Clinically evaluated in Canada and France, Prostar Plus incorporates technology from Perclose's Techstar one-suture device into a two-suture system. Perclose, which says it is "very pleased by the initial clinical experience with the Prostar Plus 8F," plans to launch the product this quarter in Europe, Japan and Canada, noting that a 10F product is under development...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel